Study identifier:D5130C00048
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of Ticagrelor Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease (CAD)
Coronary artery disease
Phase 2
No
Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets
All
123
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jan 2012 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: 1 Aspirin + Placebo | Drug: Aspirin Tablets Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study. Other Name: ASA |
Active Comparator: 2 Aspirin + clopidogrel | Drug: Clopidogrel (over encapsulated) capsule Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD) Other Name: Plavix Other Name: Clopidogrel Bisulfate Drug: Aspirin Tablets Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study. Other Name: ASA |
Experimental: 3 Aspirin + Ticagrelor | Drug: Ticagrelor Tablets Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD) Drug: Aspirin Tablets Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study. Other Name: ASA |